Sunshine Biopharma- Warrants (15/02/2027) Profit Margin

Sunshine Biopharma- Warrants (15/02/2027) (SBFMW) currently reports a profit margin of -17.01% as of March 2026. That compares with -13.88% in the prior-year period — down 22.6% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Sunshine Biopharma- Warrants (15/02/2027)'s profit margin history and peer comparisons.

Sunshine Biopharma- Warrants (15/02/2027)'s profit margin decreased from -13.88% to -17.01% — a 22.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sunshine Biopharma- Warrants (15/02/2027)'s profit margin of -17.01% is lower than the Healthcare sector average of 15.29%. That is roughly 211.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sunshine Biopharma- Warrants (15/02/2027)'s current -17.01% should be judged against Healthcare norms (sector average: 15.29%) and against SBFMW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -17.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Sunshine Biopharma- Warrants (15/02/2027), and consider following SBFMW for alerts when major investors trade the stock.